ICON (NASDAQ: ICLR), Dublin, Ireland, a global provider of
outsourced development services to the pharmaceutical, biotechnology and
medical device industries, has raised its existing 2006 guidance and
announced financial guidance for 2007.
As a result of our strong backlog and continuing new business
awards we are raising our net revenue forecast for 2006 to a range of
$448 to $452 million. Net income per diluted share is expected to be
$1.28 to $1.30 including non cash stock compensation expense in
accordance with SFAS 123R.
2007 net revenue is expected to be in the range of $530 - $550
million, an increase of 20% on the forecast 2006 revenue. Net income per
diluted share including non cash stock compensation expense in
accordance with SFAS 123R is forecast to be in the range of $1.63 -
$1.71. This represents an increase of 29% on 2006.
ICON plc is a global provider of outsourced development services to
the pharmaceutical, biotechnology and medical device industries. The
company specializes in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. ICON teams have successfully
conducted over 1,900 development projects and over 2,300 consultancy
engagements across all major therapeutic areas. ICON currently has over
4,100 employees, operating from 48 locations in 30 countries.
For more information, visit http://www.iconclinical.com or call
888/381-7923.
COPYRIGHT 2007 Worldwide
Videotex Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2007, Gale Group. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.